Treatment of dystonia

Expert Review of Neurotherapeutics

Volumn 6, Issue 6, 2006, Pages 863-886

  Bhidayasiri, Roongroj ^a,b   Tarsy, Daniel ^b,c  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c David Geffen School of Medicine at UCLA ^*  (United States)

Author keywords

Botulinum toxin; Deep brain stimulation; Dystonia; Treatment of dystonia

Indexed keywords

BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PIMOZIDE; RESERPINE; RISPERIDONE; TETRABENAZINE; TRIHEXYPHENIDYL;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DYSTONIA; FUNCTIONAL DISEASE; GLOBUS PALLIDUS; HUMAN; LETHARGY; PARKINSONISM; REVIEW; SEDATION; TARDIVE DYSKINESIA; URINARY URGENCY; URINE RETENTION; XEROSTOMIA;

BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; DOPAMINE ANTAGONISTS; DYSTONIA; HUMANS; PHYSICAL THERAPY MODALITIES;

EID: 33745487539     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.6.863     Document Type: Review

References (321)

1. Oppenheim H. Dysbasia lordotica progressiva, dystonia musculorum deformans. Neurol. Centrabl. 30, 1090-1107 (1911).
2. Flatau E, Sterling W. Progressiver Torsionspasms bie Kindern. Z Gesamte. Neurol. Psychiatr. 7, 586-612 (1911).
3. Fahn S. Concept and classification of dystonia. Adv. Neurol. 50, 1-8 (1988).
4. Hallett M. Physiology of dystonia. Adv. Neurol. 78, 11-18 (1998).
5. Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain 121, 1195-1212 (1998).
6. Schramm A, Reiners K, Naumann M. Complex mechanisms of sensory tricks in cervical dystonia. Mov. Disord. 19, 452-458 (2004).
7. Marsden CD, Harrison MJG. Idiopathic torsion dystonia. Brain 97, 793-810 (1974).
8. Bressman SB, de Leon D, Brin MF et al. Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann. Neurol. 26(5), 612-620 (1989).
9. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov. Disord. 10(2), 143-152 (1995).
10. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv. Neurol. 78, 1-10 (1998).
11. Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv. Neurol. 94, 101-107 (2004).
12. Hartmann A, Pogarell O, Oertel WH. Secondary dystonias. J. Neurol. 245(8), 511-518 (1998).
13. Manji H, Howard RS, Miller DH et al. Status dystonicus: the syndrome and its management. Brain 121(Pt 2), 243-252 (1998).
14. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35(1), 73-77 (1985). •• Current rating scales used in the evaluation of dystonia.
15. Comella CL, Stebbins GT, Goetz C et al. Teaching tape for the motor section of the Toronto western spasmodic torticollis scale. Mov. Disord. 12, 570-575 (1997). •• Teaching tape of how to perform the Toronto Western Spasmodic Torticollis Rating Scale.
16. Consky ES, Lang AE. Clinical assessment of patients with cervical dystonia. In: Therapy with botulinum toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, NY, USA 211-223 (1994).
17. Ondo WG, Desaloms JM, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov. Disord. 13(4), 693-698 (1998).
18. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36(2), 160-164 (1986).
19. Lindeboom R, de Haan RJ, Brans JWM et al. Treatment outcomes in cervical dystonia: a clinimetric study. Mov. Disord. 11, 371-376 (1996).
20. Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv. Neurol. 94, 275-286 (2004). •• Good review article on medical therapy of dystonia.
21. Goldman JG, Comella CL. Treatment of dystonia. Clin. Neuropharmacol. 26(2), 102-108 (2003).
22. Segawa M, Ohmi K, Itoh S et al. Childhood basal ganglia disease with remarkable response to L-dopa: hereditary basal ganglia disease with marked diurnal fluctuation (in Japanese). Shinryo (Tokyo) 24, 667-672 (1971).
23. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv. Neurol. 50, 377-384 (1988).
24. Ichinose H, Ohye T, Takahashi E et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet. 8, 236-242 (1994).
25. Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 56(2), 260-263 (2001).
26. Hagenah J, Saunders-Pullman R, Hedrich K et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 64(5), 908-911 (2005).
27. Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T. Molecular genetics of dopa-responsive dystonia. Biol. Chem. 380, 1355-1364 (1999).
28. Dewey RB, Muenter MD, Kishore A, Snow BJ. Long-term follow-up of levodopa responsiveness in generalized dystonia. Arch. Neurol. 55, 1320-1323 (1998).
29. Nygaard TG, Marsden CD, Fahn S. Doparesponsive dystonia: long-term treatment response and prognosis. Neurology 41, 174-181 (1991).
30. Nygaard TG, Takahashi H, Heiman G, Snow B, Fahn S, Calne D. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with doparesponsive dystonia. Ann. Neurol. 32, 603-608 (1992).
31. Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum. Mol. Genet. 5(3), 403-406 (1996).
32. Tassin J, Durr A, Bonnet AM et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 123, 1112-1121 (2000).
33. Paviour DC, Surtees RAH, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov. Disord. 19, 123-135 (2004).
34. de la Fuente-Fernandez R. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations. Clin. Neuropharmacol. 22(4), 216-219 (1999).
35. Bandmann O, Marsden CD, Wood NW. Atypical presentations of dopa-responsive dystonia. Adv. Neurol. 78, 283-290 (1998).
36. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 40(1), 66-69 (1990).
37. Nomura K, Yamamoto N, Takahashi I et al. [Bromocriptine and L-dopa therapy: comparison in a case of hereditary progressive dystonia with marked diurnal fluctuation]. No To Hattatsu 19, 244-248 (1987).
38. Fink JK, Ravin P, Argoff CE et al. Tetrahydrobiopterin administration in biopterin-deficient progressive dystonia with diurnal variation. Neurology 39, 1393-1395 (1989).
39. LeWitt PA, Miller LP, Levine RA et al. Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology 36(6), 760-764 (1986).
40. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including metaanalysis of the effect of botulinum toxin and other cure options. Eur. J. Neurol. 11(6), 361-370 (2004). •• Evidence-based review of medical therapy and botulinum toxin therapy in dystonia.
41. Defazio G, Lamberti P, Lepore V et al. Facial dystonia: clinical features, prognosis and pharmacology in 31 patients. Ital. J. Neurol. Sci. 10, 553 (1989).
42. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov. Disord. 3(1), 46-60 (1988).
43. Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv. Neurol. 50, 547-556 (1988).
44. Lang AE. Dopamine agonists in the treatment of dystonia. Clin. Neuropharmacol. 8, 38 (1985).
45. Tolosa ES. Modification of tardive dyskinesia and spasmodic torticollis by apomorphine. Arch. Neurol. 35, 459 (1978).
46. Silbergeld EK, Hruska RE. Lisuride and LSD: dopaminergic and serotonergic interactions in the "serotonin syndrome". Psychopharmacology 65, 233 (1979).
47. Stahl SM, Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 32, 889-892 (1982).
48. Quinn NP, Lang AE, Sheehy MP, Marsden CD. Lisuride in dystonia. Neurology 35, 766-769 (1985).
49. Nutt JG, Hammerstad JP, Carter JH, deGarmo PL. Lisuride treatment of focal dystonias. Neurology 35, 1242-1243 (1985).
50. Obeso JA, Luquin MR. Bromocriptine and lisuride in dystonias. Neurology 34, 135-136 (1984).
51. Hoon AH Jr., Freese PO, Reinhardt EM et al. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr. Neurol. 25(1), 55-58 (2001).
52. Jabbari B, Scherokman B, Gunderson CH, Rosenberg ML, Miller J. Treatment of movement disorders with trihexyphenidyl. Mov. Disord. 4(3), 202-212 (1989).
53. Fahn S. Treatment of dystonia with high-dose anticholinergic medication. Neurology 29, 605 (1979).
54. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 33(10), 1255-1261 (1983).
55. Lang AE. High dose anticholinergic therapy in adult dystonia. Can. J. Neurol. Sci. 13(1), 42-46 (1986).
56. Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J. Neurol. Neurosurg. Psychiatry 47(11), 1166-1173 (1984).
57. Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv. Neurol. 37, 189-192 (1983).
58. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov. Disord. 1, 193 (1986).
59. Taylor AE, Lang AE, Saint-Cyr JA, Riley DE, Ranawaya R. Cognitive processes in idiopathic dystonia treated with highdose anticholinergic therapy: implications for treatment strategies. Clin. Neuropharmacol. 14(1), 62-77 (1991).
60. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann. Neurol. 17(2), 107-116 (1985).
61. b receptors on neurones in rat brain slices. Br. J. Pharmacol. 101(4), 949-957 (1990).
62. Bowery NG, Hill DR, Hudson AL et al. (-) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 283(5742), 92-94 (1980).
63. Anca MH, Zaccai TF, Badarna S, Lozano AM, Lang AE, Giladi N. Natural history of Oppenheim's dystonia (DYT1) in Israel. J. Child Neurol. 18(5), 325-330 (2003).
64. Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov. Disord. 7(1), 48-52 (1992).
65. Greene P. Baclofen in the treatment of dystonia. Clin. Neuropharmacol. 15(4), 276-288 (1992).
66. Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can. J. Ophthalmol. 22(1), 24-28 (1987).
67. Knutsson E, Lindblom U, Martensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J. Neurol. Sci. 23(3), 473-484 (1974).
68. Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal baclofen for intractable axial dystonia. Neurology 41(7), 1141-1142 (1991).
69. Dressler D, Oeljeschlager RO, Ruther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov. Disord. 12, 585-587 (1997).
70. Albright AL, Barry MJ, Painter MJ et al. Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J. Neurosurg. 88, 73-76 (1998).
71. Albright AL, Barry MJ, Fasick P, Barron W, Shultz B. Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 38(5), 934-938 (1996).
72. Walker RH, Danisi FO, Swope DM, Goodman RR, Germano IM, Brin MF. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov. Disord. 15(6), 1242-1247 (2000).
73. Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev. Med. Child Neurol. 43(10), 652-657 (2001).
74. van Hilten JJ, Hoff JI, Thang MC, van de Meerakker MM, Voormolen JH, Delhaas EM. Clinimetric issues of screening for responsiveness to intrathecal baclofen in dystonia. J. Neural. Transm. 106(9-10), 931-941 (1999).
75. van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N. Engl. J. Med. 343(9), 625-630 (2000).
76. Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov. Disord. 16(6), 1201-1202 (2001).
77. Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients. J. Neurosurg. 91(5), 733-736 (1999).
78. Meythaler JM, Guin-Renfroe S, Hadley MN. Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Am. J. Phys. Med. Rehabil. 78, 247-254 (1999).
79. Gianino JM, York MM, Paice JA, Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J. Neurosci. Nurs. 30(1), 47-54 (1998).
80. Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, DeForge DA. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can. J. Neurol. Sci. 22(3), 208-217 (1995).
81. Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can. J. Neurol. Sci. 22(1), 22-29 (1995).
82. Ford B, Greene P, Louis ED et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch. Neurol. 53(12), 1241-1246 (1996).
83. Meythaler JM, Guin-Renfroe S, Grabb P et al. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch. Phys. Med. Rehabil. 80, 13-19 (1999).
84. Butler C, Campbell S. AACPDM Treatment outcomes committe review panel: evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev. Med. Child Neurol. 42, 634-645 (2000). •• American Academy for Cerebral Palsy and Developmental Medicine review article on the use of intrathecal baclofen in spastic and dystonic cerebral palsy.
85. Penn RD, Savoy SM, Corcos DM et al. Intrathecal baclofen for severe spinal spasticity. N. Eng. J. Med. 320, 1517-1521 (1989).
86. Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 33(2), 226-230 (1993).
87. Silbert PL, Stewart-Wynne EG. Increased dystonia after intrathecal baclofen. Neurology 42, 1639-1640 (1992).
88. Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf. 16, 180-204 (1997).
89. Burbaud P, Guehl D, Lagueny A et al. A pilot trial of clozapine in the treatment of cervical dystonia. J. Neurol. 245, 329-331 (1998).
90. Thiel A, Dressler D, Kistel C, Ruther E. Clozapine treatment of spasmodic torticollis. Neurology 44, 957-958 (1994).
91. Wolf ME, Mosnaim AD. Improvement of axial dystonia with the administration of clozapine. Int. J. Clin. Pharmacol. Ther. 32, 282-283 (1994).
92. Karp BI, Goldstein SR, Chen R, Samii A, Bara-Jimenez W, Hallett M. An open trial of clozapine for dystonia. Mov. Disord. 14(4), 652-657 (1999).
93. Raja M, Maisto G, Altavista MC, Albanese A. Tardive lingual dystonia treated with clozapine. Mov. Disord. 11, 585-586 (1996).
94. Trugman JM, Leadbetter R, Zalis ME, Burgdorf O, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov. Disord. 9, 441-446 (1994).
95. VanHarten PN, Kamphuis DJ, Matroos GE. Use of clozapine in tardive dystonia. Prog. Neuropsychopharmacol. Biol. Psychiatry 20, 263-274 (1996).
96. Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet 347(8994), 127-128 (1996).
97. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48(2), 358-362 (1997).
98. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol. 20, 425-430 (1984).
99. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin. Neuropharmacol. 27(5), 230-233 (2004).
100. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38(3), 391-394 (1988).
101. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann. Neurol. 11(1), 41-47 (1982).
102. Reches A, Hassan MN, Jackson VR, Fahn S. Lithium attenuates dopamine depleting effects of reserpine and tetrabenzine but not of α methyl-p-tyrosine. Life Sci. 33, 157-160 (1983).
103. Furukawa T, Ushizima I, Ono N. Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine. Psychopharmacologia. 42, 243-248 (1975).
104. Giladi N, Melamed E. Levodopa therapy can ameliorate tetrabenazine- induced parkinsonism. Mov. Disord. 14, 158-159 (1999).
105. Pekkenberg H, Fog R. Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both. Arch. Neurol. 31, 352-353 (1974).
106. Hughes AJ, Lees AJ, Marsden CD. Paroxysmal dystonic head tremor. Mov. Disord. 6, 85-86 (1991).
107. Obeso JA, Rothwell JC, Lang AE et al. Myoclonic dystonia. Neurology 33, 825-830 (1983).
108. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 11(Suppl. 9), S6-S10 (1994).
109. Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 53, 435-452 (1997).
110. Lang AE, Riley DE. Tizanidine in cranial dystonia. Clin. Neuropharmacol. 15, 142-147 (1992).
111. Lucetti C, Nuti A, Gambaccini G et al. Mexiletine in the treatment of torticollis and generalized dystonia. Clin. Neuropharmacol. 23, 186-189 (2000).
112. Ohara S, Hayashi R. Mexiletine in the treatment of spasmodic torticollis. Mov. Disord. 13, 934-940 (1998).
113. Ohara S, Tsuyuzaki J, Hayashi R. Mexiletine in the treatment of blepharospasm: experience with the first three patients. Mov. Disord. 14, 173-175 (1999).
114. Quinn NP, Rothwell JC, Thompson PD, Marsden CD. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv. Neurol. 50, 391-401 (1988).
115. Muller J, Wenning GK, Wissel J et al. Riluzole therapy in cervical dystonia. Mov. Disord. 17(1), 198-200 (2002).
116. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 33(3), 155-188 (1981).
117. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur. Neurol. 53(1), 3-9 (2005). •• Excellent review article on the mechanism of action of botulinum toxin.
118. Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon. 39(1), 27-41 (2001).
119. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 6(Suppl.), S146-S168 (1997).
120. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Mov. Disord. 19(Suppl. 8), S53-S59 (2004).
121. Wohlfarth K, Kampe K, Bigalke H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov. Disord. 19(Suppl. 8), S65-S67 (2004).
122. Aoki KR, Guyer B. Botulinum toxin type a and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 8(Suppl. 5), 21-29 (2001).
123. Figgitt DP, Noble S. Botulinum toxin B. A review of its therapeutic potential in the management of cervical dystonia. Drugs 62, 705-755 (2002).
124. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord. 19(Suppl. 8), S129-S136 (2004).
125. Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve 29(5), 628-44 (2004).
126. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry 53(8), 633-639 (1990).
127. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J. Neurol. Sci. 235, 1-9 (2005).
128. Cordivari C, Misra VP, Catania S, Lees AJ. New therapeutic indications for botulinum toxins. Mov. Disord. 19(Suppl. 8), S157-S161 (2004).
129. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9(2), 213-217 (1994).
130. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 45(9), 1743-1746 (1995).
131. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43, 1715-1718 (1993).
132. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J. Neurol. Neurosurg. Psychiatry 66(5), 612-616 (1999).
133. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50(6),1624-1629 (1998).
134. Kessler KR, Skutta M, Benecke R. Longterm treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J. Neurol. 246, 265-274 (1999).
135. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov. Disord. 8(4), 479-483 (1993).
136. Mezaki T, Kaji R, Hamano T et al. Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J. Neurol. Neurosurg. Psychiatry 57(12), 1535-1537 (1994).
137. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov. Disord. 13(1), 150-154 (1998).
138. Barbano RL. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve 24(11), 1567-1568 (2001).
139. Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 24(11), 1568-1570 (2001).
140. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov. Disord. 6, 119-126 (1991).
141. Bhidayasiri R, Tarsy D. Medical therapy for dystonia. In: Handbook of Dystonia. Stacy M (Ed.). Taylor & Francis, NY, USA (2005) (In Press).
142. Konrad C, Vollmer-Haase J, Anneken K, Knecht S. Orthopedic and neurological complications of cervical dystonia-review of the literature. Acta Neurol. Scand. 109, 369-373 (2004).
143. Waterston JA, Swash M, Watkins ES. Idiopathic dystonia and cervical spondylotic myelopathy. J. Neurol. Neurosurg. Psychiatry 52, 1424-1426 (1989).
144. Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. J. Neurol. Neurosurg. Psychiatry 55, 229-231 (1992).
145. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov. Disord. 6(2), 145-150 (1991).
146. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov. Disord. 12, 100-102 (1997).
147. Poewe W, Schlosky L, Kleedorfer B et al. Treatment of spasmodic torticollis with local injections of botulinum toxin. J. Neurol. 239, 21-25 (1992).
148. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 40(2), 277-280 (1990).
149. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40(8), 1213-1218 (1990).
150. Brashear A, Lew MF, Dykstra DD et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type Aresponsive cervical dystonia. Neurology 53(7), 1439-1446 (1999).
151. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J. Neurol. 249(1), 57-63 (2002).
152. Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39, 80-84 (1989).
153. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37(4), 616-623 (1987).
154. Cullis PA, O'Brien CF, Truong DD et al. Botulinum toxin type B: an open-label, dose escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv. Neurol. 78, 227-230 (1998).
155. Lew MF, Adornato BT, Duane DD et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49, 701-707 (1997).
156. Brin MF, Lew MF, Adler CH et al. Safety and efficacy of neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53(7), 1431-1438 (1999).
157. Barnes MP, Best D, Kidd L et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A-initial experiences. Eur. J. Neurol. 12(12), 947-955 (2005).
158. Comella CL, Jankovic J, Shannon KM et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65, 1423-1429 (2005).
159. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: Type B compared with type A. Neurology 49, 189-194 (1997).
160. Sloop RR, Patel MC. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals. Mov. Disord. 16, 100-105 (2001).
161. Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: longterm experience. Neurology 51, 1494-1496 (1998).
162. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Sampaio C. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst. Rev. CD004312 (2005).
163. Brans JW, Lindeboom R, Snoek JW et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46, 1066-1072 (1996).
164. Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur. J. Neurol. 12, 163-170 (2005).
165. Hsiung G-Y, Das SK, Ranawaya R et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov. Disord. 17, 1288-1293 (2002).
166. Dressler D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur. J. Neurol. 7, 713-718 (2000). •• Excellent electromyographic study in cervical dystonia (CD).
167. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75, 951-957 (2004).
168. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry 72(4), 459-462 (2002).
169. Odergren T, Hjaltason H, Kaakkola S et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry 64(1), 6-12 (1998).
170. Poewe W, Deuschl G, Nebe A et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J. Neurol. Neurosurg. Psychiatry 64, 13-17 (1998).
171. Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology 42, 1307-1310 (1992).
172. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Eur. Neurol. 49, 34-38 (2003).
173. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60, 1186-1188 (2003).
174. Grandas F, Elston J, Quinn N et al. Blepharospasm: a review of 264 patients. J. Neurol. Neurosurg. Psychiatry 51, 767-772 (1988).
175. Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov. Disord. 17, 7-12 (2002).
176. Kraft SP, Lang AE. Cranial dystonia blepharospasm, and hemifacial spasm: Clinical features and treatment, including the use of botulinum toxin. Can. Med. Assoc. J. 139, 837-844 (1988).
177. Taylor JD, Kraft SP, Kazdan MS et al. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can. J. Ophthalmol. 26, 133-138 (1991).
178. Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord. 2(4), 237-254 (1987).
179. Kennedy RH, Bartley GB, Flanagan JC, Waller RR. Treatment of blepharospasm with botulinum toxin. Mayo. Clin. Proc. 64(9), 1085-1090 (1989).
180. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 95(11), 1529-1534 (1988).
181. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv. Ophthalmol. 41(1), 51-65 (1996).
182. Borodic GE, Cozzolino D. Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast. Reconstr. Surg. 83(3), 546-554 (1989).
183. No authors listed. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. American Academy of Ophthalmology (Suppl.), 37-41 (1989).
184. American Academy of Neurology. Reports of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Training guidelines for the use of botulinum toxin for the treatment of neurological disorders. Neurology 44, 2401-2403 (1994).
185. Truong D. Efficacy and safety of botulinum type A toxin complex (Dysport) for the treatment of benign essential blepharospasm. Parkinsonism Relat. Disord. 11(Suppl. 2), 68 (2005).
186. Frueh BR, Nelson CC, Kapustiak JF, Musch DC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am. J. Ophthalmol. 106(1), 45-47 (1988).
187. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch. Ophthalmol. 102(10), 1464-1468 (1984).
188. Sampaio C, Ferreira JJ, Simoes F et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov. Disord. 12(6), 1013-1018 (1997).
189. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch. Clin. Exp. Ophthalmol. 235(4), 197-199 (1997).
190. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in rare indications. J. Neurol. 248(Suppl. 1), 39-44 (2001).
191. Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol. Scand. 103(1), 49-52 (2001).
192. Reimer J, Gilg K, Karow A, Esser J, Franke GH. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol. Scand. 111, 64-70 (2005).
193. Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology 58(12), 1843-1846 (2002).
194. Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J. Neurol. Neurosurg. Psychiatry 60(6), 704 (1996).
195. Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 104(5), 865-868 (1997).
196. Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J. Neurol. 249(1), 64-68 (2002).
197. Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq. Neuropsiquiatr. 63(2A), 221-224 (2005).
198. Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J. Neurol. Neurosurg. Psychiatry 59(3), 309-311 (1995).
199. Albanese A, Bentivoglio AR, Colosimo C, Galardi G, Maderna L, Tonali P. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J. Neurol. Neurosurg. Psychiatry 60(6), 693-694 (1996).
200. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. 103(3), 347-350 (1985).
201. Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: primary and secondary forms. Adv. Neurol. 50, 509-515 (1988).
202. Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch. Otolaryngol. Head Neck Surg. 127(4), 389-392 (2001).
203. Weiner WJ, Nausieda PA, Glantz RH. Meige syndrome (blepharospasmoromandibular dystonia) after long-term neuroleptic therapy. Neurology 31(12), 1555-1556 (1981).
204. Jankovic J. Drug-induced and other orofacial-cervical dyskinesias. Ann. Intern. Med. 94(6), 788-793 (1981).
205. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53(9), 2102-2107 (1999).
206. Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 101(11), 1216-1218 (1991).
207. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol. Rhinol. Laryngol. 98(2), 93-97 (1989).
208. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18(7), 720-729 (1995).
209. Maurri S, Brogelli S, Alfieri G, Barontini F. Use of botulinum toxin in Meige's disease. Riv. Neurol. 58(6), 245-248 (1988).
210. Laskawi R, Rohrbach S. [Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin]. Laryngorhinootologie. 80(12), 708-713 (2001).
211. Brin MF. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin type A. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, NY, USA 429-435 (1994).
212. Behari M, Singh KK, Seshadri S, Prasad K, Ahuja GK. Botulinum toxin A in blepharospasm and hemifacial spasm. J. Assoc. Physicians India 42(3), 205-208 (1994).
213. Berardelli A, Formica A, Mercuri B et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital. J. Neurol. Sci. 14(5), 361-367 (1993).
214. Aronson AE, Brown JR, Litin EM, Pearson JS. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J. Speech Hear Disord. 33(3), 219-231 (1968).
215. Aronson AE, Brown JR, Litin EM, Pearson JS. Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects. J. Speech Hear. Disord. 33(3), 203-218 (1968).
216. Leonard R, Kendall K. Differentiation of spasmodic and psychogenic dysphonias with phonoscopic evaluation. Laryngoscope 109(2 Pt 1), 295-300 (1999).
217. Ludlow CL, Connor NP. Dynamic aspects of phonatory control in spasmodic dysphonia. J. Speech Hear. Res. 30(2), 197-206 (1987).
218. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 96(11), 1300-1301 (1986).
219. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2(8501), 245-247 (1986).
220. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can. J. Neurol. Sci. 12(4), 314-316 (1985).
221. Rontal M, Rontal E, Rolnick M, Merson R, Silverman B, Truong DD. A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report. Laryngoscope 101(8), 911-914 (1991).
222. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 98(2), 193-197 (1988).
223. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 101(6 Pt 1), 630-634 (1991).
224. Ludlow CL, Naunton RF, Terada S, Anderson BJ. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection. Otolaryngol. Head Neck Surg. 104(6), 849-855 (1991).
225. Whurr R, Lorch M, Fontana H, Brookes G, Lees A, Marsden CD. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J. Neurol. Neurosurg. Psychiatry 56(5), 526-530 (1993).
226. Aronson AE, McCaffrey TV, Litchy WJ, Lipton RJ. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections. Laryngoscope 103(6), 683-692 (1993).
227. Liu TC, Irish JC, Adams SG, Durkin LC, Hunt EJ. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia. J. Otolaryngol. 25(2), 66-74 (1996).
228. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J. Speech Lang. Hear. Res. 45(3), 469-481 (2002).
229. Watts CC, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia. Cochrane Database Syst. Rev. 3, CD004327 (2004).
230. Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int. J. Lang. Commun. Disord. 33(Suppl.) 327-329 (1998).
231. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia), a 12-year experience in more than 900 patients. Laryngoscope 108(10), 1435-1441 (1998).
232. Courey MS, Garrett CG, Billante CR et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann. Otol. Rhinol. Laryngol. 109(9), 819-822 (2000).
233. Murry T, Cannito MP, Woodson GE. Spasmodic dysphonia. Emotional status and botulinum toxin treatment. Arch. Otolaryngol. Head Neck Surg. 120(3), 310-316 (1994).
234. Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 38(8), 1220-1225 (1988).
235. Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv. Neurol. 50, 599-608 (1988).
236. Sheehy MP, Rothwell JC, Marsden CD. Writer's cramp. Adv. Neurol. 50, 457-472 (1988).
237. Thompson PD. Writer's cramp. Br. J. Hosp. Med. 50, 91-94 (1993).
238. Schuele S, Jabusch HC, Lederman RJ, Altenmuller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology 64(2), 341-343 (2005).
239. Jabusch HC, Zschucke D, Schmidt A, Schuele S, Altenmuller E. Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients. Mov. Disord. 20(12), 1623-1626 (2005).
240. Frucht SJ, Fahn S, Greene PE et al. The natural history of embouchure dystonia. Mov. Disord. 16(5), 899-906 (2001).
241. Turjanski N, Pirtosek Z, Quirk J et al. Botulinum toxin in the treatment of writer's cramp. Clin. Neuropharmacol. 19, 314-320 (1996).
242. Jankovic J, Schwartz KS. Use of botulinum toxin treatment of hand dystonia. J. Hand Surg. 18A, 883-887 (1993).
243. Wissel J, Kabus C, Wenzel R et al. Botulinum toxin treatment in writer's cramp: objective response evaluation in 31 patients. J. Neurol. Neurosurg. Psychiatry 61, 172-175 (1996).
244. Cohen LG, Hallett M, Geller BD, Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections. J. Neurol. Neurosurg. Psychiatry 52, 355-363 (1989).
245. Rivest J, Lees AJ, Marsden CD. Writer's cramp: treatment with botulinum toxin injections. Mov. Disord. 6, 55-59 (1991).
246. Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov. Disord. 10, 466-471 (1995).
247. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 42, 627-630 (1992).
248. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double blind study. Neurology 43, 183-185 (1993).
249. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch. Neurol. 53, 617-624 (1996). •• Excellent study on botulinum toxin treatment in limb disorders.
250. Bertrand CM, Molina-Negro P. Selective peripheral denervation in 111 cases of spasmodic torticollis. Adv. Neurol. 50, 637-643 (1988).
251. Andrew J, Fowler CJ, Harrison MJG. Stereotaxic thalamotomy in 55 cases of dystonia. Brain 106, 981-1000 (1983).
252. Tasker RR. Surgical treatment of the dystonias. In: Textbook of Stereotactic and Functional Neurosurgery. Gildenberg PL, Tasker RR (Eds). McGraw-Hill, NY, USA 1015-1032 (1998).
253. Lenz FA, Suarez JI, Metman LV et al. Pallidal activity during dystonia: somatosensory reorganisation and changes with severity. J. Neurol. Neurosurg. Psychiatry 65(5), 767-770 (1998).
254. Vitek JL, Chockkan V, Zhang JY et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann. Neurol. 46, 22-35 (1999). •• Excellent study on neurophysiology of basal ganglia in dystonia and hemiballism.
255. Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery 52, 1358-1370 (2003).
256. Vitek JL, Zhang JY, DeLong MR, Mewes K, Bakay RAE. GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Adv. Neurol. 78, 211-219 (1998).
257. Silberstein P, Kuhn AA, Kupsch A et al. Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain 126, 2597-2608 (2003).
258. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285 (1990).
259. Vercueil L, Pollak P, Fraix V et al. Deep brain stimulation in the treatment of severe dystonia. J. Neurol. 248(8), 695-700 (2001).
260. Tronnier VM, Fogel W. Pallidal stimulation for generalized dystonia. Report of three cases. J. Neurosurg. 92(3), 453-456 (2000).
261. Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology 53(4), 871-874 (1999).
262. Krauss JK, Pohle T, Weber S, Ozdoba C, Burgunder JM. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet 354(9181), 837-838 (1999).
263. Lozano AM, Kumar R, Gross RE et al. Globus pallidus internus pallidotomy for generalized dystonia. Mov. Disord. 12(6), 865-870 (1997).
264. Vidailhet M, Vercueil L, Houeto JL et al. Bilateral deep brain stimulation of the globus pallidus in primary generalized dystonia. N. Eng. J. Med. 352, 459-467 (2005). •• Excellent prospective study on globus pallidus interna deep brain stimulation (DBS) in primary generalized dystonia.
265. Merello M, Cerquetti D, Cammarota A et al. Neuronal globus pallidus activity in patients with generalised dystonia. Mov. Disord. 19(5), 548-554 (2004).
266. Krauss JK, Yianni J, Loher TJ, Aziz TZ. Deep brain stimulation for dystonia. J. Clin. Neurophysiol. 21(1), 18-30 (2004). •• Excellent review article on DBS in dystonia.
267. Munchau A, Mathen D, Cox T, Quinn NP, Marsden CD, Bhatia KP. Unilateral lesions of the globus pallidus: report of four patients presenting with focal or segmental dystonia. J. Neurol. Neurosurg. Psychiatry 69(4), 494-498 (2000).
268. Yianni J, Bain PG, Gregory RP et al. Postoperative progress of dystonia patients following globus pallidus internus deep brain stimulation. Eur. J. Neurol. 10(3), 239-247 (2003).
269. Kumar R. Methods for programming and patient management with deep brain stimulation of the globus pallidus for the treatment of advanced Parkinson's disease and dystonia. Mov. Disord. 17(Suppl. 3) S198-S207 (2002).
270. Volkmann J, Benecke R. Deep brain stimulation for dystonia: patient selection and evaluation. Mov. Disord. 17(Suppl. 3) S112-S115 (2002). •• Excellent article on patient selection and evaluation for DBS in dystonia.
271. Parkin S, Aziz T, Gregory R, Bain P. Bilateral internal globus pallidus stimulation for the treatment of spasmodic torticollis. Mov. Disord. 16(3), 489-493 (2001).
272. Krauss JK, Loher TJ, Pohle T et al. Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J. Neurol. Neurosurg. Psychiatry 72(2), 249-256 (2002).
273. Bereznai B, Steude U, Seelos K, Botzel K. Chronic high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov. Disord. 17(1), 138-144 (2002).
274. Kyriagis M, Grattan-Smith P, Scheinberg A, Teo C, Nakaji N, Waugh M. Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J. Paediatr. Child Health 40(5-6), 322-325 (2004).
275. Angelini L, Nardocci N, Estienne M, Conti C, Dones I, Broggi G. Life-threatening dystonia-dyskinesias in a child: successful treatment with bilateral pallidal stimulation. Mov. Disord. 15(5), 1010-1012 (2000).
276. Vitek JL, Zhang J, Evatt M et al. GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Adv. Neurol. 78, 211-219 (1998).
277. Lin JJ, Lin SZ, Lin GY, Chang DC, Lee CC. Application of bilateral sequential pallidotomy to treat a patient with generalized dystonia. Eur. Neurol. 40(2), 108-110 (1998).
278. Lin JJ, Lin GY, Shih C, Lin SZ, Chang DC, Lee CC. Benefit of bilateral pallidotomy in the treatment of generalized dystonia. Case report. J. Neurosurg. 90(5), 974-976 (1999).
279. Iacono RP, Kuniyoshi SM, Lonser RR, Maeda G, Inae AM, Ashwal S. Simultaneous bilateral pallidoansotomy for idiopathic dystonia musculorum deformans. Pediatr. Neurol. 14(2), 145-148 (1996).
280. Yianni J, Bain P, Giladi N et al. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov. Disord. 18(4), 436-442 (2003).
281. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 355(9222), 2220-2221 (2000).
282. Cif L, El Fertit H, Vayssiere N et al. Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J. Neurosurg. Sci. 47(1), 52-55 (2003).
283. Eltahawy HA, Saint-Cyr J, Giladi N, Lang AE, Lozano AM. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery 54(3), 613-619 (2004).
284. Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov. Disord. 21(5), 692-695 (2005) (Epub ahead of print).
285. Halbig TD, Gruber D, Kopp UA, Schneider GH, Trottenberg T, Kupsch A. Pallidal stimulation in dystonia: effects on cognition, mood, and quality of life. J. Neurol. Neurosurg. Psychiatry 76(12), 1713-1716 (2005).
286. Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J. Neurol. Neurosurg. Psychiatry 76(9), 1188-1193 (2005).
287. Krause M, Fogel W, Kloss M, Rasche D, Volkmann J, Tronnier V. Pallidal stimulation for dystonia. Neurosurgery 55(6), 1361-1370 (2004).
288. Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A. Pallidal and thalamic neurostimulation in severe tardive dystonia. J. Neurol. Neurosurg. Psychiatry 70(4), 557-559 (2001).
289. Loher TJ, Hasdemir MG, Burgunder JM, Krauss JK. Long-term follow-up study of chronic globus pallidus internus stimulation for posttraumatic hemidystonia. J. Neurosurg. 92(3), 457-460 (2000).
290. Franzini A, Marras C, Ferroli P et al. Longterm high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J. Neurosurg. 102(4), 721-725 (2005).
291. Castelnau P, Cif L, Valente EM et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann. Neurol. 57(5), 738-741 (2005).
292. Zorzi G, Marras C, Nardocci N et al. Stimulation of the globus pallidus internus for childhood-onset dystonia. Mov. Disord. 20(9), 1194-1200 (2005).
293. Krauss JK, Toups EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry 63(5), 642-648 (1997).
294. Capelle HH, Weigel R, Krauss JK. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology 60(12), 2017-2018 (2003).
295. Houser M, Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov. Disord. 20(9), 1203-1205 (2005).
296. Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, Gomez-Galan M, Figueiras-Mendez R. Pallidal stimulation relieves myoclonus-dystonia syndrome. J. Neurol. Neurosurg. Psychiatry 76(7), 989-991 (2005).
297. Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg. Neurol. 40(2), 96-103 (1993).
298. Shima F, Fukui M, Kitamura K, Kuromatsu C, Okamura T. Diagnosis and surgical treatment of spasmodic torticollis of 11th nerve origin. Neurosurgery 22(2), 358-363 (1988).
299. Friedman AH, Nashold BS Jr., Sharp R, Caputi F, Arruda J. Treatment of spasmodic torticollis with intradural selective rhizotomies. J. Neurosurg. 78(1), 46-53 (1993).
300. Krauss JK, Koller R, Burgunder JM. Partial myotomy/myectomy of the trapezius muscle with an asleep-awake-asleep anesthetic technique for treatment of cervical dystonia. Technical note. J. Neurosurg. 91(5), 889-891 (1999).
301. Bara-Jimenez W, Shelton P, Sanger TD, Hallett M. Sensory discrimination capabilities in patients with focal hand dystonia. Ann. Neurol. 47(3), 377-380 (2000).
302. Bara-Jimenez W, Shelton P, Hallett M. Spatial discrimination is abnormal in focal hand dystonia. Neurology 55, 1869-1873 (2000).
303. Byl NN, Merzenich MM, Jenkins WM. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex ub adult monkeys. Neurology 47, 508-520 (1996).
304. Byl NN, Nagajaran S, McKenzie AL. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch. Phys. Med. Rehabil. 84(10), 1505-1514 (2003).
305. Byl NN, McKenzie A. Treatment effectiveness for patients with a history of repetitive hand use and focal hand dystonia: a planned, prospective follow-up study. J. Hand Ther. 13(4), 289-301 (2000).
306. Zeuner KE, Hallett M. Sensory training as treatment for focal hand dystonia: a 1-year follow-up. Mov. Disord. 18(9), 1044-1047 (2003).
307. Zeuner KE, Bara-Jimenez W, Noguchi PS, Goldstein SR, Dambrosia JM, Hallett M. Sensory training for patients with focal hand dystonia. Ann. Neurol. 51(5), 593-598 (2002).
308. Zeuner KE, Shill HA, Sohn YH et al. Motor training as treatment in focal hand dystonia. Mov. Disord. 20(3), 335-341 (2005).
309. Bhidayasiri R, Bronstein JM. Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Med. Hypotheses. 64(5), 941-945 (2005).
310. Ranawaya R, Lang A. Usefulness of a writing device in writer's cramp. Neurology 41(7), 1136-1138 (1991).
311. Candia V, Wienbruch C, Elbert T, Rockstroh B, Ray W. Effective behavioral treatment of focal hand dystonia in musicians alters somatosensory cortical organization. Proc. Natl Acad. Sci. USA 100(13), 7942-7946 (2003).
312. Tas N, Karatas GK, Sepici V. Hand orthosis as a writing aid in writer's cramp. Mov. Disord. 16(6), 1185-1189 (2001).
313. Murase N, Rothwell JC, Kaji R et al. Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer's cramp. Brain 128(Pt 1), 104-115 (2005).
314. Pesenti A, Barbieri S, Priori A. Limb immobilization for occupational dystonia: a possible alternative treatment for selected patients. Adv. Neurol. 94, 247-254 (2004).
315. Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov. Disord. 16, 7-12 (2001).
316. Priori A, Pesenti A, Cappellari A, Scarlato G, Barbieri S. Limb immobilization for the treatment of focal occupational dystonia. Neurology 57(3), 405-409 (2001).
317. Yoshida K, Kaji R, Kubori T, Kohara N, Iizuka T, Kimura J. Muscle afferent block for the treatment of oromandibular dystonia. Mov. Disord. 13(4), 699-705 (1998).
318. Gonzalez-Alegre P, Miller VM, Davidson BL, Paulson HL. Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann. Neurol. 53(6), 781-787 (2003).
319. Junker J, Oberwittler C, Jackson D, Berger K. Utilization and perceived effectiveness of complementary and alternative medicine in patients with dystonia. Mov. Disord. 19(2), 158-161 (2004).
320. Kock N, Allchorne AJ, Sena-Esteves M, Woolf CJ, Breakefield XO. RNAi blocks DYT1 mutant torsinA inclusions in neurons. Neurosci. Lett. 395(3), 201-205 (2006).
321. Lansbury PT Jr. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat. Med. 10(Suppl.) S51-S57 (2004).